Edding Genor Group Holdings (HKSE:06998) EBIT: HK$ Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06998 Edding Genor Group Holdings Ltd HKSE:06998
15 GF Score
Price HK$1.53
! 1 Warning Sign
View Full Analysis

What is Edding Genor Group Holdings EBIT?

Edding Genor Group Holdings HKSE:06998 +0.33% 15 EBIT is HK$ Mil as of Dec. 2025. GuruFocus rates HKSE:06998 with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

Edding Genor Group Holdings's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was HK$730 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Edding Genor Group Holdings's annualized ROC % for the quarter that ended in Dec. 2025 was 9.04%. Edding Genor Group Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 135.02%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Edding Genor Group Holdings  (HKSE:06998) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Edding Genor Group Holdings's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=708.808 * ( 1 - 19.55% )/( (6371.447 + 6246.214)/ 2 )
=570.236036/6308.8305
=9.04 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5808.169 - 773.203 - ( 119.262 - max(0, 3151.545 - 1815.064+119.262))
=6371.447

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7293.994 - 1059.261 - ( 1165.413 - max(0, 2442.507 - 2431.026+1165.413))
=6246.214

Note: The Operating Income data used here is one times the annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Edding Genor Group Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=730.33/( ( (329.737 + max(390.618, 0)) + (361.483 + max(-9.1020000000003, 0)) )/ 2 )
=730.33/( ( 720.355 + 361.483 )/ 2 )
=730.33/540.919
=135.02 %

where Working Capital is:

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(341.147 + 590.183 + 467.918) - (773.203 + 0 + 235.427)
=390.618

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(697.569 + 477.542 + 59.89) - (1059.261 + 0 + 184.842)
=-9.1020000000003

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Edding Genor Group Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=/3482.964
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edding Genor Group Holdings EBIT Related Terms

Edding Genor Group Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Edding Genor Group Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edding Genor Group Holdings EBIT Chart

Edding Genor Group Holdings Annual Data
Trend Dec24 Dec25
EBIT
792.26 730.33

Edding Genor Group Holdings Semi-Annual Data
Dec24 Dec25
EBIT 792.26 730.33

HKSE:06998 vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Edding Genor Group Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Edding Genor Group Holdings EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Edding Genor Group Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Edding Genor Group Holdings's EV-to-EBIT falls into.


HKSE:06998
15GF Score
Edding Genor Group Holdings Ltd HKSE:06998
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edding Genor Group Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$ Mil mean?
Edding Genor Group Holdings (HKSE:06998) has a EBIT of HK$ Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Edding Genor Group Holdings.
Is Edding Genor Group Holdings' EBIT too high?
Edding Genor Group Holdings' current EBIT is HK$ Mil. Overall, Edding Genor Group Holdings has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Edding Genor Group Holdings' EBIT compare to ZTS?
Edding Genor Group Holdings' EBIT of HK$ Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Edding Genor Group Holdings. Edding Genor Group Holdings's current EBIT is HK$ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edding Genor Group Holdings stock overvalued right now?
Edding Genor Group Holdings (HKSE:06998) has a current EBIT of HK$ Mil. The current EBIT is HK$ Mil. Edding Genor Group Holdings' overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Edding Genor Group Holdings (HKSE:06998), the current EBIT is HK$ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edding Genor Group Holdings Business Description

Address No. 36 Doukou Road, Room 406, Building 1, Hengqin New Area, Guangdong Province, Zhuhai, CHN
Edding Genor Group Holdings Ltd is an integrated specialty biopharmaceutical company, focusing on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. Through the acquisition of branded drug assets from multinational pharmaceutical companies (MNCs) and licensing in development and commercialisation rights of patented drugs from international biopharmaceutical companies, it has established a portfolio of originator-branded and other drugs. The company has two reportable operating segments: Manufacturing and Distribution, which generates the maximum revenue, and Research and development. Geographically, it derives maximum revenue from the Chinese mainland, and the rest from the USA and other markets.
15GF Score

Get the complete analysis for HKSE:06998

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.53
Price